• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $IPA

    ImmunoPrecise Antibodies Ltd.

    Subscribe to $IPA
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has a research collaboration agreement with Pierre Fabre S.A for antibody discovery. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

    IPO Year:

    Exchange: NASDAQ

    Website: immunoprecise.com

    Recent Analyst Ratings for ImmunoPrecise Antibodies Ltd.

    DatePrice TargetRatingAnalyst
    12/2/2022$9.00Buy
    H.C. Wainwright
    10/25/2021$12.00Buy
    Benchmark
    10/25/2021$12.00Buy
    The Benchmark Company
    See more ratings

    ImmunoPrecise Antibodies Ltd. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on ImmunoPrecise Antibodies with a new price target

      H.C. Wainwright initiated coverage of ImmunoPrecise Antibodies with a rating of Buy and set a new price target of $9.00

      12/2/22 8:15:24 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Benchmark initiated coverage on ImmunoPrecise Antibodies with a new price target

      Benchmark initiated coverage of ImmunoPrecise Antibodies with a rating of Buy and set a new price target of $12.00

      10/25/21 7:31:59 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • The Benchmark Company initiated coverage on ImmunoPrecise Antibodies with a new price target

      The Benchmark Company initiated coverage of ImmunoPrecise Antibodies with a rating of Buy and set a new price target of $12.00

      10/25/21 7:28:32 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ImmunoPrecise Antibodies downgraded by Industrial Alliance Securities

      Industrial Alliance Securities downgraded ImmunoPrecise Antibodies from Buy to Hold

      2/9/21 1:35:03 PM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    ImmunoPrecise Antibodies Ltd. SEC Filings

    See more
    • SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.

      6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)

      7/24/25 9:40:10 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.

      6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)

      7/21/25 9:50:55 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.

      6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)

      7/14/25 9:31:46 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.

      6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)

      7/7/25 9:16:40 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.

      6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)

      7/3/25 9:40:55 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.

      6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)

      6/24/25 8:00:38 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.

      6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)

      6/12/25 8:25:06 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.

      6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)

      6/5/25 8:11:08 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.

      6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)

      5/21/25 8:00:04 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.

      6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)

      5/12/25 9:55:49 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    ImmunoPrecise Antibodies Ltd. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic

      ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a Bio-Native AI pioneer operating where TechBio meets true biological intelligence, today announced results of a newly expanded study demonstrating that its LENSai™ Immunogenicity Screening can reliably predict Anti-Drug-Antibody (ADA) risk for therapeutic proteins before they enter animal studies or human trials. "ADA-related failures still derail up to 40 percent of biologics in late development, costing companies billions of dollars," said Dr. Jennifer Bath, President & CEO, IPA. "With LENSai, we can now triage candidates against clinical data in hours, not months, giving drug-developers a fast, objective way to de-ri

      7/24/25 8:22:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board

      ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced the appointment of Jeff Fried to its Advisory Board. A recognized leader in healthcare data infrastructure and AI innovation, Jeff Fried brings more than 25 years of experience designing and delivering high-performance data for complex life sciences and clinical environments. He currently serves as Director of Platform Strategy and Innovations for InterSystems, where he helps shape high-performance data solutions for some of the world's most demanding healthcare and life sciences environments. He has serve

      7/21/25 8:28:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025

      The Company to host an earnings conference call via webcast ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for fourth quarter and full fiscal year end 2025, on Tuesday, July 29, 2025, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a question-and-answer period. Conference Call and Webcast Details The Company will host a live confere

      7/16/25 8:05:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement

      ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a company operating at the convergence of TechBio and biological intelligence, today announced that it has received formal notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), concerning the minimum bid price requirement. The notice, dated July 11, 2025, stated that for the 10 consecutive business days from June 26, 2025, through July 10, 2025, the closing bid price of the Company's common shares was at or above $1.00 per share. As a result, ImmunoPrecise has satisfied the requirements for continued listing on the Nasdaq Capital

      7/14/25 8:01:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors

      ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), an AI-powered biotherapeutics company, today announced the appointment of Jon Lieber to its Board of Directors, effective immediately. Mr. Lieber brings over 30 years of financial and strategic leadership across the biotechnology and life sciences sectors, with deep expertise in capital markets, investor relations, and corporate development. He currently serves as Chief Financial Officer at Rallybio, a clinical-stage biotechnology company developing therapies for severe and rare diseases. He also brings valuable experience in Nasdaq governance, having served as both a senior executive and board member of publicly traded

      7/7/25 9:00:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology

      Follow-Up to June 5, 2025, Announcement Demonstrates Validated Vaccine Candidate with Strong Translational Potential ImmunoPrecise (NASDAQ:IPA), a leader in AI-driven biotherapeutics, provides a significant update following its June 5, 2025, press release ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery. This new release details the downstream validation of the epitope identified in that initial announcement—demonstrating that the computationally selected vaccine target is not only highly conserved across all four dengue virus types but also safe, immunologically active, and structurally stable. "This is a major step forward," said Dr. Jennifer Bath,

      6/24/25 7:02:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies

      Breakthrough in AI-powered drug discovery validates HYFT™-driven peptide design, with broad potential across multiple therapeutic areas ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), a leader in AI-powered drug discovery and biotherapeutics, today announced compelling in vitro results demonstrating that its artificial intelligence (AI)-designed GLP-1 receptor agonist (GLP-1RA) peptide sequences achieve comparable or superior receptor activation to Semaglutide, a benchmark GLP-1 therapy and one of the most commercially successful drugs in the world. The in vitro analysis was conducted by an independent third party, further strengthening the objectivity and reliability of the findings. The r

      6/12/25 8:01:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery

      LENSai™ powered by HYFT® technology Identifies a single multi-factorial target conserved across all dengue serotypes. ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, announces discovery of a highly conserved epitope across all four dengue virus serotypes using its proprietary LENSai™ platform powered by their patented HYFT® technology. This discovery, made using several proprietary HYFT-based analyses, identifies a part of the virus (an epitope) that has remained unmutated across all four known virus serotypes, therefore potentially allowing an epitope-based vaccine to target and activate the immune system to eliminate the virus. This discovery mark

      6/5/25 8:01:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts

      ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, today announced it has engaged CORE IR, a strategic investor and public relations firm, to support the Company's ongoing investor relations and communications initiatives. CORE IR specializes in working with emerging and established growth companies to enhance investor awareness, strengthen shareholder engagement, and broaden outreach to various institutional and retail audiences. "This collaboration with CORE IR represents an important step in IPA's ongoing commitment to improving our communication with the investment community and increasing market visibility," said Dr. Jennifer Bath, CEO of ImmunoPr

      5/21/25 8:49:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ImmunoPrecise Antibodies (IPA) to Present at Maxim Group's 2025 Virtual Tech Conference

      Tuesday, June 3rd at 11:00 a.m. EDT ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, today announced that Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies Ltd., will be presenting at the Maxim Group's virtual conference: 2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow   Hosted by: Maxim Group LLC Date: June 3rd – 5th Presentation Time: Tuesday, June 3rd at 11:00AM EDT Location: Virtual (M-Vest Platform) Registration: Click here to register The rapid evolution of technology is paving the way for disruption across all industries, including healthcare, drones, consumer IoT,

      5/20/25 8:28:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    ImmunoPrecise Antibodies Ltd. Leadership Updates

    Live Leadership Updates

    See more
    • ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board

      ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced the appointment of Jeff Fried to its Advisory Board. A recognized leader in healthcare data infrastructure and AI innovation, Jeff Fried brings more than 25 years of experience designing and delivering high-performance data for complex life sciences and clinical environments. He currently serves as Director of Platform Strategy and Innovations for InterSystems, where he helps shape high-performance data solutions for some of the world's most demanding healthcare and life sciences environments. He has serve

      7/21/25 8:28:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors

      ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), an AI-powered biotherapeutics company, today announced the appointment of Jon Lieber to its Board of Directors, effective immediately. Mr. Lieber brings over 30 years of financial and strategic leadership across the biotechnology and life sciences sectors, with deep expertise in capital markets, investor relations, and corporate development. He currently serves as Chief Financial Officer at Rallybio, a clinical-stage biotechnology company developing therapies for severe and rare diseases. He also brings valuable experience in Nasdaq governance, having served as both a senior executive and board member of publicly traded

      7/7/25 9:00:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ImmunoPrecise Antibodies Announces Key Leadership Changes

      ImmunoPrecise Antibodies (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, is pleased to announce key leadership updates, including the appointment of Kamil Isaev to its Board of Directors and Joseph Scheffler as Interim Chief Financial Officer (CFO). Additionally, IPA announces the planned departure of Chris Buyse from the Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250224016053/en/Kamil Isaev (Photo: Business Wire) Kamil Isaev Joins IPA's Board of Directors IPA is pleased to welcome Dr. Isaev, a seasoned technology leader and venture strategist, to its

      2/24/25 8:01:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IPA Announces Resignation of Chief Financial Officer

      ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) today announced that Kristin Taylor has resigned from her position as Chief Financial Officer effective January 16, 2025. Ms. Taylor will continue to serve in the role of CFO until January 16, 2025, and will remain available to the company on a consulting basis after that time. "Kristin has been a valued member of our team over this past year," said Dr. Jennifer Bath, IPA's President and Chief Executive Officer. "She has made significant contributions to IPA's success, including the enhancement of IPA's planning and budgeting process. We wish her the very best in her future endeavors." IPA has initiated a CFO succession process and will p

      12/31/24 7:56:00 PM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ImmunoPrecise Antibodies Celebrates Nobel Prize in Chemistry, Advances in AI-Powered Protein Design

      University of Washington's Baker Lab and Google DeepMind Redefine Protein Science, Paving the Way for AI-Driven Biotherapeutics ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today celebrates the recent Nobel Prize in Chemistry awarded to David Baker of the University of Washington, Seattle, WA, USA, "for computational protein design," and jointly to Demis Hassabis and John M. Jumper of Google DeepMind, London, UK, "for protein structure prediction." This accolade highlights the vital role of computational tools and AI in advancing our understanding of protein structures—principles that are central to IPA's

      10/10/24 8:10:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer

      ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, is pleased to announce the appointment of Kristin Taylor as Chief Financial Officer, effective immediately. Ms. Taylor has been serving as Interim CFO since September 19th, 2023, and now transitions into the role on a permanent basis. Ms. Taylor is a seasoned financial executive with extensive experience in both early-stage and large growth companies, including those privately held, private equity-backed, and publicly listed. She has a strong background in driving growth, establishing infrastructure, and implementing effective strategies for value creation in d

      6/27/24 8:01:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioStrand, ImmunoPrecise Antibodies' Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery

      -BioStrand now offers a Customizable Application Programming Interface (API) with its new software offering, LENSai API, featuring the ability to integrate sizable databases and electronic health records with large language models. -BioStrand's novel software is rapidly and directly integrable into pharmaceutical, healthcare, and technology companies to enhance drug discovery capabilities. -This proprietary software provides the integration of electronic health records, enhancing AI-driven drug discovery and development for industry professionals. ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("ImmunoPrecise" or "IPA" or the "Company"), a leader in AI-driven biotherapeutic research and t

      6/10/24 7:15:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments

      Significant throughput of LSA to advance IPA's diversity- and data-driven drug development and to enrich LENSai™. IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an artificial intelligence-driven biotherapeutic research and technology company, today announced that it has acquired the LSA® instrument platform from Carterra®, a leading provider of high-throughput large and small molecule screening and characterization solutions. This instrument allows for high throughput surface plasmon resonance-based antibody characterizations thereby significantly increasing the Company's capacity in performing various label-free protein interaction analyses including best-in-c

      3/20/24 7:02:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IPA Announces Board Refreshment

      IPA appoints Barry A. Springer, Dirk Witters and Chris Buyse to the Board of Directors IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an advanced biotherapeutic research and technology company, is pleased to announce that further to its news release dated August 9, 2023, it has appointed, in its search for optimal Board composition, Barry A. Springer, Dirk Witters and Chris Buyse to the Board of Directors of the Company. APPOINTMENT OF NEW DIRECTORS TO THE BOARD OF DIRECTORS In surveying the new appointees, Dr. James Kuo, Chair of the Board of IPA, highlighted the following: "It is a testament to our Board's reputation for transparency and shareholder eng

      9/5/23 8:00:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IPA Announces Resignation of Director

      IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ:IPA) (TSXV:IPA) announced today that Paul Andreola, a member of the Board of Directors of IPA, has resigned, effective immediately, from the Company's Board of Directors for personal reasons unrelated to the Company. "On behalf of the Company and the Board of Directors, I would like to thank Paul for serving on our Board of Directors. His insightful and experienced contributions were highly valued, and we wish Paul all the best in his future endeavours," commented Jennifer Bath, President and Chief Executive Officer and director of the Company. Mr. Andreola commented, "It has been a privilege to serve on the board since 2018.

      11/9/21 7:52:00 PM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    ImmunoPrecise Antibodies Ltd. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by ImmunoPrecise Antibodies Ltd.

      SC 13G - ImmunoPrecise Antibodies Ltd. (0001715925) (Subject)

      2/27/24 10:33:04 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ImmunoPrecise Antibodies Ltd. (Amendment)

      SC 13G/A - ImmunoPrecise Antibodies Ltd. (0001715925) (Subject)

      1/10/24 1:53:08 PM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ImmunoPrecise Antibodies Ltd.

      SC 13G - ImmunoPrecise Antibodies Ltd. (0001715925) (Subject)

      1/10/24 1:33:21 PM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by ImmunoPrecise Antibodies Ltd.

      SC 13D - ImmunoPrecise Antibodies Ltd. (0001715925) (Subject)

      7/7/23 3:22:18 PM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    ImmunoPrecise Antibodies Ltd. Financials

    Live finance-specific insights

    See more
    • IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025

      The Company to host an earnings conference call via webcast ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for fourth quarter and full fiscal year end 2025, on Tuesday, July 29, 2025, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a question-and-answer period. Conference Call and Webcast Details The Company will host a live confere

      7/16/25 8:05:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025

      Secures $8-$10M Strategic Partnership Scales AI Infrastructure Collaborations with Vultr and Leading Providers of Advanced GPU technologies to Accelerate de novo Drug Discovery. Unlocking Margin Expansion Through Scalable AI IPA Strengthens Board & Management Team Kamil Isaev, Joseph Scheffler, and Dr. Li Hui join IPA, enhancing leadership in AI, finance, and client relations. IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today reported financial results for the third quarter ("Q3") of its 2025 fiscal year ("FY25"), which ended January 31, 2025. "As we continue to revolutionize the AI-enabled drug disc

      3/28/25 8:01:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025

      The Company to host an earnings conference call via webcast ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a global leader in AI-powered antibody discovery and development, today announces the rescheduling of its Third Quarter Fiscal 2025 financial results and business highlights release. Originally set for March 13, 2025, the new release date is Friday, March 28, 2025, and IPA will hold an earnings call at 10:30 am Eastern Time the same day. The Company is providing additional time to allow its auditors to complete the necessary reviews and audit requirements on valuation calculations of goodwill and intangible assets. This extension ensures that the financial data

      3/11/25 10:17:00 PM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025

      The Company to host an earnings conference call via webcast ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a global leader in AI-powered antibody discovery and development, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for third quarter fiscal year 2025, on Thursday, March 13, 2025, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a question-and-answer period. Conference Call and Webcast Details The Company will host a live conference call and webcast to discuss these results and

      3/5/25 8:01:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025

      Delivers $6.1 Million Q2 Revenue and Announces Strategic Plan to Reshape Biotech and AI-Driven Drug Discovery IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today reported financial results for the second quarter ("Q2") of its 2025 fiscal year ("FY25"), which ended October 31, 2024. All numbers are expressed in Canadian dollars, unless otherwise noted. "This quarter marks a pivotal chapter for IPA as we unveil our cutting-edge in silico drug discovery tools, designed to revolutionize the landscape of novel therapeutic development. These advanced platforms offer unprecedented insights and precision, aimed

      12/10/24 8:30:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 on December 10, 2024

      The Company to host an earnings conference call via webcast IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for second quarter fiscal year 2025, on Tuesday, December 10, 2024, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a question-and-answer period. Conference Call and Webcast Details The Company will host a live conference call and webcast to discuss these resul

      12/3/24 8:30:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025

      Achieves $5.3 Million First Quarter Revenue, Reaches Milestone Developing Antibodies End-to-End Using LENSai IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ:IPA), an artificial intelligence-driven biotherapeutic research and technology company, today reported financial results for the first quarter of its 2025 fiscal year ("FY25"), which ended July 31, 2024. All numbers are expressed in Canadian dollars, unless otherwise noted. "Our commitment to end-to-end in silico engineering of antibodies for challenging targets has delivered exceptional results. By harnessing our advanced computational capabilities, we've not only accelerated our R&D process, but also significantly red

      9/16/24 9:00:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on September 16, 2024

      The Company to host an earnings conference call via webcast IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an artificial intelligence-driven biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for first quarter fiscal year 2025, on Monday, September 16, 2024, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a question-and-answer period. Conference Call and Webcast Details The Company will host a live conference call and webcast to d

      9/9/24 9:11:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ImmunoPrecise Antibodies (IPA) Reports Financial Results and Business Updates for Fourth Quarter and Full Fiscal Year 2024

      Achieves Record $24.5 Million Revenue in FY 2024, Showcases Technological Advancements Expands Laboratory Capabilities and Launches Advanced AI Models, Aimed at Strengthening Market Position Launches Commercial LENSai API, Offering Advanced AI-Powered Solutions Across Multiple Markets and Prepares for Further Launch with its Newest Partner, AWS ImmunoPrecise Antibodies Ltd. ("IPA", "Company", "we" or "us") (NASDAQ:IPA), an artificial intelligence (AI)-driven biotherapeutic research and technology company, today announced its financial results for the fiscal year ended April 30, 2024. All numbers are expressed in Canadian dollars unless otherwise noted. "IPA has achieved significant

      7/29/24 8:30:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ImmunoPrecise Antibodies to Reschedule Financial Results and Recent Business Highlights Report for Fourth Quarter and Fiscal Year-End 2024

      The Company to host an earnings conference call via webcast ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ:IPA) today announces the rescheduling of its full year fiscal 2024 financial results and business highlights release. Originally set for July 25, 2024, the new release date is Monday, July 29, 2024, and will hold an earnings call at 10:30 am Eastern Time the same day. The Company is providing additional time to allow its auditors to complete the necessary valuation calculations on goodwill and intangible assets. This extension ensures that the financial data accurately reflects the Company's value and complies with all regulatory requirements. The delay will allow f

      7/23/24 7:30:00 PM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care